First Results from Phase 3 Trial Expected to Support FDA’s Accelerated Approval of Voxelotor for Sickle Cell
News
Once-daily treatment with voxelotor, Global Blood Therapeutics’ lead therapy candidate, can effectively increase the amount of hemoglobin in about 58% of patients with sickle cell disease (SCD) in just 12 weeks, ... Read more